Literature DB >> 33949936

Treatment for Diabetic Peripheral Neuropathy: What have we Learned from Animal Models?

Mark Yorek1,2,3.   

Abstract

INTRODUCTION: Animal models have been widely used to investigate the etiology and potential treatments for diabetic peripheral neuropathy. What we have learned from these studies and the extent to which this information has been adapted for the human condition will be the subject of this review article.
METHODS: A comprehensive search of the PubMed database was performed, and relevant articles on the topic were included in this review.
RESULTS: Extensive study of diabetic animal models has shown that the etiology of diabetic peripheral neuropathy is complex, with multiple mechanisms affecting neurons, Schwann cells, and the microvasculature, which contribute to the phenotypic nature of this most common complication of diabetes. Moreover, animal studies have demonstrated that the mechanisms related to peripheral neuropathy occurring in type 1 and type 2 diabetes are likely different, with hyperglycemia being the primary factor for neuropathology in type 1 diabetes, which contributes to a lesser extent in type 2 diabetes, whereas insulin resistance, hyperlipidemia, and other factors may have a greater role. Two of the earliest mechanisms described from animal studies as a cause for diabetic peripheral neuropathy were the activation of the aldose reductase pathway and increased non-enzymatic glycation. However, continuing research has identified numerous other potential factors that may contribute to diabetic peripheral neuropathy, including oxidative and inflammatory stress, dysregulation of protein kinase C and hexosamine pathways, and decreased neurotrophic support. In addition, recent studies have demonstrated that peripheral neuropathy-like symptoms are present in animal models, representing pre-diabetes in the absence of hyperglycemia.
CONCLUSION: This complexity complicates the successful treatment of diabetic peripheral neuropathy, and results in the poor outcome of translating successful treatments from animal studies to human clinical trials. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Diabetes; and animal models; diabetic neuropathy; hyperglycemia; hyperlipidemia; insulin resistance

Mesh:

Year:  2022        PMID: 33949936      PMCID: PMC8965779          DOI: 10.2174/1573399817666210504101609

Source DB:  PubMed          Journal:  Curr Diabetes Rev        ISSN: 1573-3998


  213 in total

1.  Are ACE inhibitors a "magic bullet" against oxidative stress?

Authors:  T Münzel; J F Keaney
Journal:  Circulation       Date:  2001-09-25       Impact factor: 29.690

2.  Enalapril attenuates oxidative stress in diabetic rats.

Authors:  E M de Cavanagh; F Inserra; J Toblli; I Stella; C G Fraga; L Ferder
Journal:  Hypertension       Date:  2001-11       Impact factor: 10.190

3.  Evidence for functional endothelin-converting enzyme activity in isolated rat basilar artery: effect of inhibitors.

Authors:  H Vatter; L Schilling; P Schmiedek; H Ehrenreich
Journal:  J Cardiovasc Pharmacol       Date:  1998       Impact factor: 3.105

4.  Polyols and myo-inositol in diabetic neuropathy--of mice and men.

Authors:  D R Tomlinson
Journal:  Mayo Clin Proc       Date:  1989-08       Impact factor: 7.616

5.  The effect of exercise on neuropathic symptoms, nerve function, and cutaneous innervation in people with diabetic peripheral neuropathy.

Authors:  Patricia M Kluding; Mamatha Pasnoor; Rupali Singh; Stephen Jernigan; Kevin Farmer; Jason Rucker; Neena K Sharma; Douglas E Wright
Journal:  J Diabetes Complications       Date:  2012-06-18       Impact factor: 2.852

6.  Effect of increased concentration of D-glucose or L-fucose on monocyte adhesion to endothelial cell monolayers and activation of nuclear factor-kappaB.

Authors:  Mark A Yorek; Joyce A Dunlap
Journal:  Metabolism       Date:  2002-02       Impact factor: 8.694

7.  Effect of a prostaglandin I2 derivative (iloprost) on peripheral neuropathy of diabetic rats.

Authors:  A Ohno; A Kanazawa; A Tanaka; T Miwa; H Ito
Journal:  Diabetes Res Clin Pract       Date:  1992-11       Impact factor: 5.602

8.  Ranirestat (AS-3201), a potent aldose reductase inhibitor, reduces sorbitol levels and improves motor nerve conduction velocity in streptozotocin-diabetic rats.

Authors:  Takafumi Matsumoto; Yoshiyuki Ono; Masuo Kurono; Akemi Kuromiya; Keiji Nakamura; Vera Bril
Journal:  J Pharmacol Sci       Date:  2008-07       Impact factor: 3.337

9.  Exercise-mediated improvements in painful neuropathy associated with prediabetes in mice.

Authors:  Anna L Groover; Janelle M Ryals; Brianne L Guilford; Natalie M Wilson; Julie A Christianson; Douglas E Wright
Journal:  Pain       Date:  2013-08-06       Impact factor: 6.961

10.  High concentration of glucose induces the expression of intercellular adhesion molecule-1 in human umbilical vein endothelial cells.

Authors:  S Takami; S Yamashita; S Kihara; K Kameda-Takemura; Y Matsuzawa
Journal:  Atherosclerosis       Date:  1998-05       Impact factor: 5.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.